SYSTEMATIC REVIEW article
Front. Public Health
Sec. Health Economics
This article is part of the Research TopicInnovative Value-Based Medicine: Lessons From China’s and APAC’s Healthcare Evolution, Volume IIView all 7 articles
Efficacy, Safety, and Costs of Nine Chinese Patent Medicines for the Treatment of angina pectoris in CHD
Provisionally accepted
- 1City University of Hong Kong, Kowloon, Hong Kong, SAR China
- 2Sichuan University, Chengdu, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objective: This study employed a multidimensional evaluation framework (of efficacy, safety, and costs) to comprehensively assess the value of Chinese patent medicines (CPMs) combined with Western medicine in treating coronary heart disease (CHD) angina pectoris with Qi deficiency and blood stasis pattern. Methods: Efficacy analysis was based on a network meta-analysis (NMA) of 24 randomized controlled trials (RCTs). Safety was assessed using a standardized framework that graded adverse events via CTCAE v5.0 and synthesized risk profiles into a Composite Safety Score. A pragmatic Cost-Consequence Analysis (CCA) was employed to synthesize direct daily treatment costs with clinical efficacy rankings (SUCRA). Results: The network meta-analysis of 24 RCTs (n=2,382) showed that CPMs combined with conventional medicine significantly improved clinical efficacy (OR 3.08, 95% CI: 2.46– 3.85). Dengzhan Shengmai Capsule (SUCRA 88.99%) and Shexiang Tongxin Dropping Pill (SUCRA 75.12%) ranked highest in efficacy. Safety analysis using the Composite Safety Score (CSS) identified Yangxinshi Tablet as having the most favorable profile (CSS=3), whereas Xintong Granule and Qishen Capsule presented higher risks (CSS=9) due to hepatotoxicity concerns or data gaps. Cost-consequence analysis revealed distinct value profiles: Yangxinshi Tablet offered the lowest daily cost (CNY 6.24) suitable for cost-minimization; Shexiang Tongxin Dropping Pill (CNY 7.28) provided a balanced cost-efficacy ratio; while Dengzhan Shengmai Capsule (CNY 10.86) represented a premium high-efficacy option. Sensitivity analysis confirmed the robustness of efficacy findings but highlighted cost fluctuations in flexible-dose regimens. Conclusion: Specific CPMs, notably Dengzhan Shengmai Capsule (maximal efficacy), Shexiang Tongxin Dropping Pill (balanced value), and Yangxinshi Tablet (cost-minimization), demonstrate significant therapeutic and economic advantages as add-on therapies. Beyond these clinical findings, this study establishes a multidimensional framework aligned with international regulatory standards, serving as a model for the future pharmacoeconomic integration of TCM into global cardiovascular care.
Keywords: Angina pectoris (AP), Chinese patent medicine (CPM), cost-consequence analysis (CCA), Network meta-analysis (NMA), Qi deficiency and blood stasis
Received: 31 Aug 2025; Accepted: 15 Dec 2025.
Copyright: © 2025 Sun, Yang, Zhou, Ruixuan, Wang, Ying and Hu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Jiahui Sun
Nan Yang
Naitong Zhou
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.